Stories about Data monitoring committee
-
Language:
English
-
Content:
All
- Date:
- Date:
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Astellas Pharma Europe Limited
Medivation and Astellas Announce the Phase 3 PREVAIL Trial of XTANDI?(TM) (Enzalutamide) Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients with Advanced Prostate Cancer
1